Real World Evidence of a Successful Oncology Trial Rescue in Canada
Each clinical study presents unique challenges, and it’s not unusual despite every effort that a clinical trial does not proceed…
How Does Your CRO’s Feasibility Process Contribute to Your Clinical Trial Success?
In clinical research, the process of finding and selecting sites is essential to the success of a study, as it…
Where Are the Phase I and II Oncology Trials in Canada?
For every phase I and II oncology trial taking place in Canada, there are almost 8-fold more phase I and…
Will Canada’s Multi-Center Approval Processes Help Your Oncology Clinical Trial Exceed Pivotal Milestones?
For the Sponsor choosing Canada to help meet and exceed pivotal corporate objectives on their oncology trial, First Site Opened…
Exploring a ‘Rescue’ Strategy for Your Oncology Clinical Trial?
Although not formally defined within the industry, the term ‘rescue’ is commonly linked with clinical trials where enrollment is falling…
Navigating Canadian Regulations for Oncology Clinical Research – Part II
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part II Senior executives from oncology drug developers looking to…
20 Years of Unparalleled Canadian Oncology Clinical Research Experience
Scimega Research, Canada’s premier oncology contract research organization (CRO), was founded twenty years ago by two dynamic entrepreneurs, Denise Deakin…
Navigating Canadian Regulations for Oncology Clinical Research – Part I
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part I Senior executives from oncology drug developers looking to…
Proven Approach to Site Selection is Attracting More Cutting-Edge Oncology Trials to Canada
12 Early-Phase Oncology Programs Started-Up in Canada Over Last 18-Months
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded
Leveraging Canada For Quicker Oncology Site Start-Up
A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study.